The U.S. Food and Drug Administration (opens in new tab) on Monday approved Bayer's Sunharbo (asundexian) 50 mg tablets to reduce the risk of stroke in adults who recently had a mild-to-moderate ischemic stroke not caused by a clot from the heart, or a high-risk transient ischemic attack, often called a mini-stroke. It is used together with antiplatelet therapy. The FDA said it is the first approved drug that works by blocking the clotting protein Factor XIa.

In the OCEANIC-STROKE trial of 12,327 adults, who started the drug or a placebo within 72 hours of symptoms, Sunharbo cut the risk of ischemic stroke by 26% over a median of 14.2 months of treatment, the FDA said. Overall major bleeding was similar between the groups, but it was higher with Sunharbo in patients older than 75 and during the first 90 days. Gastrointestinal bleeding was more common on the drug, and diarrhea was the most frequent side effect. It is not approved for stroke prevention in people with atrial fibrillation.

Widely used blood thinners such as Eliquis and Xarelto block a different protein, Factor Xa, Reuters reported. "Today's approval represents a meaningful advance for patients and health care providers seeking a new option for secondary stroke prevention," said Hylton Joffe, who directs the FDA office that reviewed the drug.

A 30-day supply will carry a list price of $748.50, a Bayer spokesperson told BioPharma Dive (opens in new tab). "We believe that we're bringing a practice-changing innovation to the market," Sebastian Guth, president of Bayer's U.S. operations, told Reuters. China's drug regulator approved the drug late last month, Reuters reported. Rival Factor XI drugs, including Bristol Myers Squibb and Johnson & Johnson's milvexian and Novartis' abelacimab, have not yet reported late-stage stroke-prevention results.